Try as we might, we can’t cover all the biotech news out there! Here’s a roundup of European biotech news that didn’t quite make the cut over the last week or so.
- Autolus Therapeutics announced promising safety results from the ongoing phase I study of its CAR T-cell therapy.
- Swiss medical device company Novostia raised €5.7M to start first clinical trials of its heart valve prosthesis.
- Follow on data from a phase III trial of Swiss biotech Santhera’s drug idebenone shows it slows the loss of lung function in patients with the genetic disease Duchenne muscular dystrophy by 50% per year.
- German biotech Medigene treated the first patient in its phase I/II trial of its T-cell receptor modified T cell therapy for a number of different blood cancers.
- French biotech Theranexus released disappointing preliminary results from the phase II trial of its narcolepsy candidate drug, showing no significant improvements over standard therapy.
- A UK-based trial of a therapy derived from nerve cells for treatment of Parkinson’s disease appeared to repair brain cells involved in the condition, but had no significant impact on patient symptoms.
- Scottish biotech TC Biopharm will collaborate with Trinity College in Dublin to speed up development of its gamma-delta T cell banks for treating solid tumors. Initial clinical trials of the treatments are planned for later this year.
- Roche and Immatics are collaborating to test the safety and effectiveness of the German biotech’s anti-cancer cell therapy in combination with Roche’s antibody-based drug atezolizumab for treatment of solid tumors.
Regulations and funding
- Themis Bioscience, an Austrian biotech focusing on infectious diseases and cancer, received fast track designation from the US FDA for its Chikungunya vaccine candidate.
- Austrian biotech Marinomed will receive €15M in funding from the European Investment Bank to continue to develop its innovative allergy, respiratory and eye disease therapies.
- Samsara Therapeutics, a European biotech developing anti-aging therapies, has received undisclosed seed funding from Apollo Ventures, a VC also focusing on age-related disease. The VC is also helping the company build its scientific team.
- Biocartis’ DNA mismatch repair diagnostic for testing of colorectal cancer tumors has received a CE mark, allowing it to be marketed alongside the Belgian company’s existing colorectal cancer test.
- FIT Biotech, a listed Finnish biotech focusing on gene therapy vectors, filed for bankruptcy after its key funder Alpha Blue Ocean failed to pay the company the €500,000 it owed them under an earlier financing agreement.
- Early data from UK-US biotech Summit Therapeutics suggests it may have found a new antibiotic for treating gonorrhea, including multi- and extensively-drug resistant strains.
Images via E. Resko